J&J to invest €100 million into Limerick manufacturing facilities creating 100 new jobs

Healthcare conglomerate Johnson & Johnson has said it will be investing €100 million into the expansion of its Vision Care manufacturing facilities in Limerick. The expansion is expected to see the creation of 100 new jobs.
The Minister of State for Trade, Employment and Business, Deputy Pat Breen celebrated the investment in calling it a “huge vote of confidence” in Ireland’s mid-west.
“The expansion, supported by the Government through the IDA, reflects the commitment of the Government and its agencies to pursue balanced and sustainable regional development,” Minister Breen said.
“We believe that the new manufacturing roles being introduced in Limerick in 2019 will be foundational in helping us bring new, innovative contact lens products to our patients and customers around the world at an industry-leading pace,” Vision Care’s plant leader, John Lynch said.
The CEO of IDA Ireland – the agency responsible for attracting and retaining foreign investment – Martin Shanahan commented: “The approximately 100 jobs being added, along with those being created in the construction phase, will greatly benefit the economy of the Mid-West region.
“Having a company of this stature continue to expand its operations enhances Ireland’s global reputation as a Medical Technologies centre of excellence and demonstrates how global companies can successfully operate in regional locations. I wish John and his team continued success.”
Louis Goss
- Login or register to post comments
- Printer-friendly version
Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches
Related content
- J&J COVID-19 vaccine to resume Europe rollout
- Johnson & Johnson to contribute a further $1 billion to US opioid settlement
- J&J halts COVID-19 vaccine study following unidentified participant illness
- Novavax and Janssen commit 90 million COVID-19 vaccine doses to UK Government with two new deals
- J&J under fire from 170 nonprofits to halt baby powder sales worldwide because it contains asbestos